Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:KODNASDAQ:LENZNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.39-4.0%$4.82$3.36▼$8.14$811.07M0.764.39 million shs5.11 million shsKODKodiak Sciences$4.03-2.4%$3.28$1.92▼$11.60$212.59M2.42346,885 shs317,680 shsLENZLENZ Therapeutics$28.96-1.4%$24.69$14.42▼$38.93$815.11M0.41186,226 shs147,233 shsZYMEZymeworks$11.61-3.4%$11.82$8.21▼$17.70$807.79M1.24603,089 shs428,154 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-2.49%-5.36%-20.85%-36.05%-54.57%KODKodiak Sciences+9.55%-16.06%+89.45%-22.66%+14.40%LENZLENZ Therapeutics+11.50%+0.93%+44.97%+18.05%+86.71%ZYMEZymeworks+6.28%-6.46%+13.08%-9.28%+36.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.5539 of 5 stars4.52.00.04.42.62.50.6KODKodiak Sciences3.6812 of 5 stars3.01.00.04.61.43.30.6LENZLENZ Therapeutics1.8208 of 5 stars3.60.00.00.03.12.50.0ZYMEZymeworks2.5123 of 5 stars3.40.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39206.46% UpsideKODKodiak Sciences 2.00Hold$9.00123.33% UpsideLENZLENZ Therapeutics 3.17Buy$46.6060.91% UpsideZYMEZymeworks 2.88Moderate Buy$21.0080.88% UpsideCurrent Analyst Ratings BreakdownLatest KOD, ARDX, ZYME, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.003/12/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.24N/AN/A$0.73 per share4.64KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/AZYMEZymeworks$93.38M8.65N/AN/A$6.63 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A10.94N/A-11.73%-24.87%-10.51%N/AKODKodiak Sciences-$260.49M-$3.36N/AN/AN/AN/A-84.52%-45.40%5/13/2025 (Estimated)LENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%N/AZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%N/ALatest KOD, ARDX, ZYME, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025KODKodiak Sciences-$0.89N/AN/AN/AN/AN/A5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/A3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A2/20/2025Q4 2024ARDXArdelyx$0.02$0.02N/A$0.02$111.16 million$116.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31KODKodiak SciencesN/A8.428.42LENZLENZ TherapeuticsN/A28.6328.63ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%KODKodiak Sciences89.06%LENZLENZ Therapeutics54.32%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.90%KODKodiak Sciences45.30%LENZLENZ Therapeutics38.40%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableKODKodiak Sciences9052.75 million28.79 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/AZYMEZymeworks46069.58 million67.56 millionOptionableKOD, ARDX, ZYME, and LENZ HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Shares Sold by Granahan Investment Management LLCMay 12 at 6:35 AM | marketbeat.comFarallon Capital Management LLC Sells 31,026 Shares of Zymeworks Inc. (NYSE:ZYME)May 11 at 7:40 AM | marketbeat.comDimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)May 11 at 3:51 AM | marketbeat.comZymeworks May 2025 slides: Pipeline expansion amid modest revenue growthMay 10 at 6:42 PM | investing.comZymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster PresentationsMay 10 at 6:42 PM | nasdaq.comZymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call TranscriptMay 10 at 6:42 PM | msn.comZymeworks Inc. (NYSE:ZYME) Shares Bought by Voya Investment Management LLCMay 10 at 4:10 AM | marketbeat.comZymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 10 at 12:10 AM | finanznachrichten.deZymeworks outlines robust pipeline advancements and financial resilience through 2027May 10 at 12:10 AM | msn.comZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 10 at 12:10 AM | finance.yahoo.comZymeworks Inc. (ZYME) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZymeworks Inc. 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comZymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comBlackstone Inc. Has $8.34 Million Stock Position in Zymeworks Inc. (NYSE:ZYME)May 8, 2025 | marketbeat.comRaymond James Financial Inc. Takes $888,000 Position in Zymeworks Inc. (NYSE:ZYME)May 8, 2025 | marketbeat.comJazz Pharmaceuticals Stock Price, Quotes and ForecastsMay 7, 2025 | benzinga.comZymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.comZymeworks (ZYME) Projected to Post Earnings on ThursdayMay 6, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from BrokeragesMay 5, 2025 | americanbankingnews.comAcuta Capital Partners LLC Acquires Shares of 67,240 Zymeworks Inc. (NYSE:ZYME)May 4, 2025 | marketbeat.comInvesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, ARDX, ZYME, and LENZ Company DescriptionsArdelyx NASDAQ:ARDX$3.39 -0.14 (-3.97%) As of 04:00 PM EasternArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Kodiak Sciences NASDAQ:KOD$4.03 -0.10 (-2.42%) As of 04:00 PM EasternKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.LENZ Therapeutics NASDAQ:LENZ$28.96 -0.41 (-1.40%) As of 04:00 PM EasternLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Zymeworks NYSE:ZYME$11.61 -0.41 (-3.41%) As of 04:00 PM EasternZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
